10-K: MAIA Biotechnology Reports Promising Survival Data for THIO in Lung Cancer Trial; Files 10-K

MAIA Biotechnology's 10-K filing highlights positive survival data from its THIO-101 Phase 2 clinical trial in non-small cell lung cancer (NSCLC) and outlines the company's financial status and future plans.

Summary

• MAIA Biotechnology, Inc., a clinical-stage biopharmaceutical company, filed its 10-K report for the fiscal year ended December 31, 2024.
• The company is focused on developing targeted immunotherapies for cancer, with its lead asset, THIO, currently in Phase 2 clinical trials.
• THIO is being evaluated in sequential combination with immune checkpoint inhibitors for the treatment of advanced NSCLC.
• The company plans to initiate a Phase 3 pivotal trial, THIO-104, in 2025 to evaluate THIO in third-line NSCLC patients resistant to checkpoint inhibitors and chemotherapy.
• MAIA is also planning Phase 2 clinical trials in HCC, CRC, and SCLC in 2026, evaluating THIO in combination with BeiGene's tislelizumab.
• The company reported positive updated data from the THIO-101 Phase 2 trial, showing a median overall survival of 16.9 months in third-line NSCLC patients.
• MAIA has entered into clinical supply agreements with Regeneron and BeiGene to support its clinical trials.
• The company's financial statements include a going concern note due to recurring losses and the need for additional capital.
• MAIA is pursuing accelerated approval for THIO in NSCLC based on clinical data from the THIO-101 study, with a potential filing in 2026.
• The company's strategy involves advancing clinical programs, broadening THIO's development, developing a franchise of telomere-targeting treatments, leveraging regulatory strategies, entering strategic collaborations, and expanding its intellectual property portfolio.

Sentiment

Score: 6

Explanation: The document presents a mixed sentiment. Positive clinical trial results are balanced by concerns about financial stability and the need for future capital raises. The company's progress in clinical development is encouraging, but the financial risks temper the overall outlook.

Positives

• Positive survival data from the THIO-101 Phase 2 trial suggests potential efficacy in NSCLC.
• Clinical supply agreements with Regeneron and BeiGene reduce costs and provide access to checkpoint inhibitors.
• FDA's RPDD designation for THIO in PDHGG provides potential for a priority review voucher.
• The company has a strategy to broaden THIO's development into multiple tumor types and treatment lines.
• Continued insider investment through independent board members participation in private placement equity financings, with funding of more than $12M year-to-date as of June 6, 2024.

Negatives

• The company has a limited operating history and has incurred losses since its formation.
• There is substantial doubt about the company's ability to continue as a going concern without additional capital.
• The company is heavily dependent on the success of THIO, which is still under clinical development.
• Clinical trials are expensive, time-consuming, and involve uncertain outcomes.
• The regulatory approval processes of the FDA and comparable foreign authorities are lengthy, time consuming, expensive, and inherently unpredictable.

Risks

• The company's ability to obtain additional funding is uncertain.
• Clinical trials may be delayed or unsuccessful.
• Regulatory approval may not be granted or may be limited.
• The company faces competition from other biotechnology and pharmaceutical companies.
• The company's intellectual property may be challenged or infringed.
• The company is dependent on third-party manufacturers and CROs.
• The company's success depends on key personnel.
• The company is subject to healthcare laws and regulations.
• The company is operating in a period of economic uncertainty and capital markets disruption.

Future Outlook

MAIA plans to initiate a Phase 3 pivotal trial in 2025 and seek accelerated approval for THIO in the United States in 2026. The company also plans to initiate Phase 2 clinical trials in HCC, CRC, and SCLC in 2026.

Management Comments

• Our goal is to be the leader in the discovery, development and commercialization of cancer telomere targeting agents and other similar small molecules.
• Ultimately, our goal would be to position THIO as a patient anticancer immunity priming treatment for all immune-activating agents used in the treatment of cancer.

Industry Context

The announcement comes amid increasing interest in telomere-targeting therapies for cancer, as evidenced by the recent FDA approval of imetelstat from Geron Corporation. MAIA is positioning THIO as a foundational priming treatment to be used prior to all checkpoint inhibitors, tapping into the large and growing checkpoint inhibitor market.

Comparison to Industry Standards

• The overall response rate (ORR) of 38% observed in the THIO-101 Phase 2 trial for third-line NSCLC patients (THIO 180mg) compares favorably to the ~6% ORR typically seen with currently available treatments in a similar population.
• The median progression-free survival (PFS) of 5.5 months (3L, THIO 180mg) in the THIO-101 trial also represents a potentially significant improvement over existing therapies.
• The disease control rate (DCR) of 85% in third-line patients in the THIO-101 trial is superior to current chemotherapy options, which range from 25-35% DCR.
• The median overall survival (OS) of 16.9 months for the 22 NSCLC patients who received at least one dose of THIO in parts A and B of the trial surpasses comparable standard-of-care overall survival of 5.8 months.

Related Party Transactions

• The consulting firm FGMK, LLC and its affiliate FGMK Business Holdings, LLC beneficially owned more than 5 % of the stock of the Company and is therefore a related party.
• On November 13, 2024, the Company expensed $ 67,990 related to the grant of 28,448 restricted shares of Common Stock for payment of their accounting, tax and valuation services.
• In addition, FGMK Business Holdings, LLC participated in the December 2024 private placement and purchased 243,470 shares of the Company's Common Stock and warrants to purchase 243,470 shares of the Company's Common Stock for an aggregate purchase price of approximately $ 550,000 .
• The following Company directors participated in the March 2024 private placement as follows: (i) Stan Smith purchased 170,940 shares of our Common Stock and warrants to purchase up to 170,940 shares of our Common Stock for an aggregate purchase price of approximately $ 200,000 ; (ii) Louie Ngar Yee purchased 170,940 shares of our Common Stock and warrants to purchase up to 170,940 shares of our Common Stock for an aggregate purchase price of approximately $ 200,000 ; (iii) Cristian Luput purchased 69,282 shares of our Common Stock and warrants to purchase up to 69,282 shares of our Common Stock for an aggregate purchase price of approximately $ 81,060 ; (iv) Steven Chaouki purchased 34,641 shares of our Common Stock and warrants to purchase up to 34,641 shares of our Common Stock for an aggregate purchase price of approximately $ 40,530 ; and (v) Ramiro Guerrero purchased 6,928 shares of our Common Stock and warrants to purchase up to 6,928 shares of our Common Stock for an aggregate purchase price of approximately $ 8,106 .
• The following Company directors participated in the April 2024 private placement as follows: (i) Stan Smith purchased 147,492 shares of our Common Stock and warrants to purchase up to 147,492 shares of our Common Stock for an aggregate purchase price of approximately $ 300,000 ; and (ii) Louie Ngar Yee purchased 19,665 shares of our Common Stock and warrants to purchase up to 19,665 shares of our Common Stock for an aggregate purchase price of approximately $ 40,000 .
• The following Company directors participated in the November 2024 private placement as follows: (i) Stan Smith purchased 100,000 shares of our Common Stock and warrants to purchase up to 100,000 shares of our Common Stock for an aggregate purchase price of approximately $ 225,900 ; (ii) Ramiro Guerrero purchased 88,534 shares of our Common Stock and warrants to purchase up to 88,534 shares of our Common Stock for an aggregate purchase price of approximately $ 200,000 ; (iii) Cristian Luput purchased 22,133 shares of our Common Stock and warrants to purchase up to 22,133 shares of our Common Stock for an aggregate purchase price of approximately $ 50,000 ; and (iv) Steven Chaouki purchased 22,133 shares of our Common Stock and warrants to purchase up to 22,133 shares of our Common Stock for an aggregate purchase price of approximately $ 50,000 . In addition, the son of Company director Stan Smith purchased 40,000 shares and 40,000 warrants for an aggregate purchase price of approximately $ 90,360 and 5 % stockholder FGMK Business Holdings, LLC purchased 243,470 shares and 243,470 warrants for a purchase price of approximately $ 550,000 .
• The following Company directors participated in the December 2024 private placement as follows: (i) Stan Smith purchased 25,000 shares of our Common Stock and warrants to purchase up to 25,000 shares of our Common Stock for an aggregate purchase price of approximately $ 46,800 ; and (ii) Ramiro Guerrero purchased 53,418 shares of our Common Stock and warrants to purchase up to 53,418 shares of our Common Stock for an aggregate purchase price of approximately $ 100,000 . In addition, Sylvia Guerrero, the sister of one of the Company directors, purchased 5,341 shares and 5,341 warrants for an aggregate purchase price of approximately $ 10,000 .

Stakeholder Impact

• Shareholders may experience dilution from future equity offerings.
• Employees' stock options and compensation may be affected by the company's financial performance.
• Patients with NSCLC and other cancers may benefit from the development of THIO.
• Suppliers and CROs may be impacted by the company's ability to fund its operations.

Next Steps

• Initiate Phase 3 pivotal trial (THIO-104) in 2025.
• Seek accelerated approval for THIO in the United States in 2026.
• Initiate Phase 2 clinical trials in HCC, CRC, and SCLC in 2026.
• Continue to evaluate THIO in other solid tumor indications.

Key Dates

Keywords

THIO, NSCLC, cancer, clinical trial, biotechnology, ateganosine, telomere, immunotherapy, FDA, Regeneron, BeiGene